Raveh received marketing approval in the US: The share is up 170% on Wall Street
About a week after receiving approval for the same product in Europe, Reuch won many public relations when she brought to the market a product that allows the disabled to go through a robotic exoskeleton, but the revenues from this product were lower than expected
A single company
(6.3938 + 21.79%)
(ReWalk) has announced that it has received marketing approval in the United States for its product for the treatment of stroke victims, about a week after receiving approval for the same product in Europe.
On Tuesday, the company’s share rose 5%, and now it is up 170% at the opening of trading on Wall Street. The company’s market value is only $ 15 million, but if the gains are maintained in trading, it could reach a value of $ 41.5 million.
Ravek won many public relations when she brought to the market a product that allows the disabled to go through a robotic external frame, but the revenues from this product were lower than expected and the share of the company crashed. The company hopes that through the new product, it will be able to restore its status.
ReStore Exo-Suit is designed for stroke patients, allowing them to practice walking during the rehabilitation process. This product differs from the company’s first product, both because it is suitable for older patients whose upper body function is not optimal and because it is designed for walking, not for daily use.
The company’s first product was designed to be paralyzed due to an injury whose upper body is normal and strong, but their legs are permanently paralyzed, and the goal was to use it as a kind of auxiliary foot, a wheelchair replacement. Thus, the first product was sold to patients (and did not receive sufficient insurance compensation, which is one of the reasons for its limited success), while the new product will be sold to rehabilitation clinics.